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In this work we report the activity seen with combination therapy using sodium antimony gluconate in
liposomes composed of egg phosphatidyl choline and stearylamine for elimination of Leishmania donovani
parasites from the liver and spleen of BALB/c mice with established and chronic infections.
Despite extended treatment regimens, parenteral adminis-
tration, and toxic side effects, the pentavalent antimonial so-
dium antimony gluconate (SAG) has remained the first-line
treatment for visceral leishmaniasis (VL) or kala-azar for de-
cades (19, 33). Frequent therapeutic failures with SAG neces-
sitate the use of more toxic second-line drugs, amphotericin B
and pentamidine (22, 23, 25). Recently several lipid-based for-
mulations of amphotericin B with reduced levels of toxicity
have been used (9, 11, 32). However, no commercial lipid
formulations of SAG are available even though liposome-en-
capsulated SAG is 200 to 700 times more active than free SAG
(2, 5, 28). In most of these studies the efficacy demonstrated by
neutral and negatively charged liposomal formulations of SAG
was determined purely on the basis of liver parasite burdens (2,
5, 21). These formulations either failed to contain parasites in
the spleen (6) or required multiple doses for a significant
clearance in an acute-infection model (7, 13). The spleen is a
site of persistent infection with Leishmania donovani (1, 12,
32), and parasite removal from this organ is more difficult than
parasite removal from liver (6, 8, 31, 32). Earlier, Dey et al.
reported on a multiple-dose treatment of drug-free, positively
charged liposomes comprising egg phosphatidylcholine (PC)
and stearylamine (SA) for the elimination of parasites from the
liver and spleen of BALB/c mice with established L. donovani
infection (10). Herein we evaluate a single-dose treatment with
PC-SA liposome encapsulating a suboptimal concentration of
SAG against an established and a chronic infection of L. do-
novani at both the sites of infection.
To optimize phospholipid composition the nonderivative
L--PC was replaced with dimyristoyl (DMPC), distearoyl
(DSPC), and dipalmitoyl (DPPC) derivatives of PC in combi-
nation with SA in a 7:2 molar ratio as detailed earlier (10). For
drug encapsulation the lipid film was dispersed in 20 mM
phosphate-buffered saline (PBS; pH 7.0) containing 1 mg of
SAG (Gluconate Health Limited, Calcutta, India)/ml and son-
icated for 30 s in an ultrasonicator. To remove free drug,
liposomes with entrapped SAG were washed in PBS with cen-
trifugation (10,000  g, 30 min, 4°C) (15). Approximately 300
to 400 g of SAG was associated with 22 mg of lipid, estimated
as described previously (2, 17).
In vitro antileishmanial drug therapy was investigated as
described earlier (10). Initially, four drug-free cationic lipo-
somes, DSPC-SA, DMPC-SA, DPPC-SA, and PC-SA, each at
88 g/ml, were tested against intracellular L. donovani amas-
tigotes for optimum activity and minimum toxicity. Whereas
DSPC-SA and DPPC-SA could not clear parasite infection by
96 h, DMPC-SA and PC-SA were almost equally effective at
the time points studied (Fig. 1). However, while DMPC-SA
induced 5% toxicity towards macrophages, as determined by
lactate dehydrogenase release in supernatants (14) at 88 g/ml,
an identical dose of PC-SA exhibited no toxic effect. Hence,
* Corresponding author. Mailing address: Indian Institute of Chem-
ical Biology, 4 Raja S.C. Mullick Rd., Calcutta 700032, India. Phone:
009133 24733491. Fax: 009133 24735197. E-mail: nali@iicb.res.in.
FIG. 1. Effect of different phospholipids with SA-bearing lipo-
somes on the survival of L. donovani amastigotes in mouse peritoneal
macrophages. Cells were infected with L. donovani promastigotes and
incubated with 88 g/ml concentrations of DPPC-SA (A), DSPC-SA
(B), DMPC-SA (C), and PC-SA (D) or an equivalent amount of re-
spective neutral liposomes or PBS for 0 to 96 h at 37°C. Data represent
the means  standard errors from triplicate coverglasses of one ex-
periment representative of two performed.
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PC-SA was selected for combination therapy with SAG. Sub-
sequently, the antileishmanial activity of SAG-loaded PC-SA
liposomes was compared with the results seen with empty
liposomes and free SAG. Liposomal SAG therapy was found
significantly more potent than either of the monotherapies (Fig.
2). The 50% effective doses for suppression of parasite infec-
tion in macrophages calculated using sigmoidal regression analy-
sis (Microsoft Excel) for empty PC-SA and free SAG were 38.26
and 69.57 g/ml, respectively. In contrast, 0.5 g of entrapped
SAG in 22.39 g of PC-SA/ml could induce an equal effect.
In vivo 8-week-infected BALB/c mice (10) were treated with
a single dose of free SAG (16 mg/kg of body weight) or empty
PC-SA (22 mg/mouse) or an equivalent dose of SAG en-
trapped in PC-SA (22 mg) (Fig. 3). Mice were sacrificed on
days 1, 15, and 30 posttreatment, and levels of organ parasite
burden were determined and expressed in Leishman Donovan
units (1). Empty liposome or free SAG could suppress infec-
tion by 15 or 50%, respectively, only in the liver, with almost no
reduction in the spleen 15 days posttreatment. On day 30,
parasite suppression increased to 48% in liver and 60% in
spleen (P  0.05) with empty liposomes and to 76% in liver
(P  0.0001) and 65% in spleen (P  0.05) with free SAG.
Combination therapy was most effective, reducing the parasite
burden by 89 and 98% in liver and 98 and 97% in spleen (P 
0.0001) at 15 and 30 days posttreatment, respectively, com-
pared to the results seen with controls. The fall in parasitemia
induced by combination therapy was significantly higher (P 
0.05) than that seen with either of the monotherapies in both
the organs.
Until recently splenectomy was the last recourse in cases of
antimony resistance (25, 29). We thus examined the efficacy of
combined treatment for mice after 3 months of infection, when
splenic parasite load is well expressed (10). Interestingly, it was
found that although the treatment efficiency declined with
empty liposome and SAG to 16 and 50% (P  0.05) in liver
and 43 (P  0.05) and 26% in spleen, respectively, at 30 days
posttreatment, almost complete clearance of parasitemia from
spleen (96%) and liver (98%), with a significant decrease in
spleen weight (69%; P  0.0001), was still achieved with the
combination therapy in this model compared to the results
seen with controls. Estimation of levels of serum alkaline phos-
phatase and glutamate pyruvate transaminase, specific en-
zymes related to liver dysfunction, and of levels of serum urea
and creatinine, related to kidney dysfunction, 15 days postin-
jection of SAG entrapped in PC-SA liposome demonstrated
levels within normal range, indicating no toxicity under the
given conditions.
Herein we report a profound synergistic activity of SAG
entrapped in PC-SA liposome in both in vitro and in vivo
models of VL. To our knowledge this is the first report of a
single dose of liposomal SAG treatment resulting in an almost
complete elimination of parasites not only from the liver but
also from the spleen of infected animals. An equivalent dose of
free SAG or empty PC-SA liposome was only partially effective
at clearing the intracellular amastigotes. Apart from a sphin-
FIG. 2. Activities of empty PC-SA liposomes, free SAG, and PC-
SA-encapsulated SAG against L. donovani amastigotes in resident
peritoneal macrophages from BALB/c mice. Cells were infected with
L. donovani promastigotes and incubated with increasing concentra-
tions of PC-SA (A), SAG (B), and PC-SA-entrapped SAG (C) for 72 h
at 37°C. Levels of infection efficiency (percent infected cells [top pan-
els]), intracellular growth (parasites per infected cell [middle panels]),
and parasite survival (parasite per 100 cells [bottom panels]) of drug-
treated cells are shown. Infected control macrophages contained
8.03  0.117 amastigotes per macrophage. The bars show the standard
errors for three replicates and are representative of two independent
experiments.
FIG. 3. Combined therapy with PC-SA liposomes, free SAG, and
PC-SA-encapsulated SAG for treatment of established and chronic
murine VL. Eight-week-infected BALB/c mice were treated intrave-
nously with a single dose of 22 mg of empty PC-SA liposomes or free
SAG (16 mg/kg of body weight) or an equivalent dose of SAG en-
trapped in 22 mg of PC-SA liposomes. Control infected animals re-
ceived only PBS. (A and B) Mice were sacrificed on days 1, 15, and 30
posttreatment. Levels of parasite burden in liver (A) and spleen
(B) are expressed in Leishman Donovan units. (C and D) In the
second set, efficacy of the combination therapy for treatment of heavy
parasite infection was assessed (12 weeks). Liver (C) and spleen
(D) parasite loads after 1 month of treatment are shown in Leishman
Donovan units. Values represent the means  standard errors of the
means for four animals per group per time point.
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gomyelin-cholesterol-SA liposomal preparation of SAG, ear-
lier formulations of SA-bearing liposomes demonstrated much
less activity than negatively charged ones (2), resulting in fol-
low-ups largely conducted with negatively charged (5, 21) and
neutral (7, 28) vesicles. Although these formulations demon-
strated spectacular success against liver parasites (2, 5, 6, 28),
they failed to perform in spleens (6). There are considerable
discrepancies in ideas as to how charges affect the interaction
of liposomes with macrophages and their distribution in vivo.
In contrast to previous observations (16, 20, 24), there are
increasing reports of improved delivery of drug-entrapped pos-
itively charged liposomes to the liver as well as the spleen over
the results seen with neutral and negatively charged vesicles (3,
18) and of better uptake by macrophages (27, 30) and efficient
parasite clearance. The efficacies of most antileishmanials, in-
cluding SAG, depend on the duration of infection, and the
effect is more evident in the spleen than the liver (4, 26). A
low-dose (16 mg/kg) activity of SAG observed even against a
chronic infection in liver and spleen, hitherto not reported, can
be attributed to a synergistic leishmanicidal activity of the
PC-SA vesicles. Our preliminary investigations suggest revers-
ible electrostatic interaction between PC-SA liposomes and
parasite plasma membranes, damage of the cellular organiza-
tion, and inhibition of parasite oxygen consumption. Studies
are under way to optimize the combination therapy for com-
plete cures.
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